"Aurora Kinase A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An aurora kinase that localizes to the CENTROSOME during MITOSIS and is involved in centrosome regulation and formation of the MITOTIC SPINDLE. Aurora A overexpression in many malignant tumor types suggests that it may be directly involved in NEOPLASTIC CELL TRANSFORMATION.
| Descriptor ID |
D064096
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.103.500 D12.776.167.049.500
|
| Concept/Terms |
Aurora Kinase A- Aurora Kinase A
- Aurora A Kinase
- Aurora A Kinases
- Aurora Kinases A
- STK15 Kinase
- AURORA2 Protein
- AuroraA Kinase
- Breast-Tumor-Amplified Kinase
- Breast Tumor Amplified Kinase
- BTAK Protein
- Serine-Threonine Protein Kinase 15
- Serine Threonine Protein Kinase 15
- AURKA
- Aurora-A Kinase
|
Below are MeSH descriptors whose meaning is more general than "Aurora Kinase A".
Below are MeSH descriptors whose meaning is more specific than "Aurora Kinase A".
This graph shows the total number of publications written about "Aurora Kinase A" by people in this website by year, and whether "Aurora Kinase A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 3 | 4 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 3 | 0 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aurora Kinase A" by people in Profiles.
-
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2025 Feb 03; 31(3):479-490.
-
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors. J Immunother Cancer. 2024 Aug 28; 12(8).
-
eEF1A2 promotes PTEN-GSK3?-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal. 2024 03 05; 17(826):eadh4475.
-
Aurora kinase A-mediated phosphorylation triggers structural alteration of Rab1A to enhance ER complexity during mitosis. Nat Struct Mol Biol. 2024 Feb; 31(2):219-231.
-
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):815-824.
-
Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro Oncol. 2023 02 14; 25(2):386-397.
-
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo. Cancer Chemother Pharmacol. 2023 02; 91(2):191-201.
-
Comparison of the genomic alterations present in tumor samples from patients with metastatic inflammatory versus non-inflammatory breast cancer reveals AURKA as a potential treatment target. Breast. 2023 Jun; 69:476-480.
-
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Res. 2022 09 02; 82(17):3088-3101.
-
Integrative ontology and pathway-based approach identifies distinct molecular signatures in transcriptomes of esophageal squamous cell carcinoma. Adv Protein Chem Struct Biol. 2022; 131:177-206.